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Doxorubicin (DOX) is ranked among anthracycline chemoterapeutics, significantly 
participant in the treatment of solid tumors, inclusive breast carcinoma and haematologic 
malignancies. DOX is metabolized to 13-OH-doxorubicinol (DOX-OL) produced by carbonyl 
reductase 1 (CBR1).  DOX-OL is lower antineoplastic, but more cardiotoxic compared to the 
parent drug. Aim of this work was research of reduction DOX and testing possible increasing 
cytotoxicity of DOX through inhibition his reductase. For experiments has been selected 
human breast cancer cell line MCF-7. Initially has been elicit optimal composition of cultural 
medium and optimalized process on sample preparation for HPLC. In the study of DOX 
metabolism in cytosol the MCF-7 cells act oracin (potentional chemoterapeutic) as 
significantly kompetition’s inhibitor of DOX reductases. In cytotoxicity tests acted DOX 
more toxic in cells with bovine serum in medium, oracin was again more toxic in cells 
without bovine serum. Combination DOX with oracin acted more toxic than single DOX to 
tumor cells MCF-7.   
 
 
